PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.59M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
6.10%
Positive revenue growth while QCOM is negative. John Neff might see a notable competitive edge here.
6.17%
Positive gross profit growth while QCOM is negative. John Neff would see a clear operational edge over the competitor.
15.50%
Positive EBIT growth while QCOM is negative. John Neff might see a substantial edge in operational management.
15.25%
Positive operating income growth while QCOM is negative. John Neff might view this as a competitive edge in operations.
14.66%
Net income growth 1.25-1.5x QCOM's 12.44%. Bruce Berkowitz would see if strategic cost cutting or product mix explains this difference.
16.67%
EPS growth similar to QCOM's 15.62%. Walter Schloss would assume both have parallel share structures and profit trends.
16.92%
Similar diluted EPS growth to QCOM's 15.87%. Walter Schloss might see standard sector or cyclical influences on both firms.
-1.40%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
-1.52%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
-0.30%
Dividend reduction while QCOM stands at 12.56%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
71.83%
OCF growth under 50% of QCOM's 421.58%. Michael Burry might suspect questionable revenue recognition or rising costs.
82.73%
FCF growth under 50% of QCOM's 304.92%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
52.13%
10Y revenue/share CAGR under 50% of QCOM's 336.13%. Michael Burry would suspect a lasting competitive disadvantage.
6.46%
5Y revenue/share CAGR under 50% of QCOM's 118.34%. Michael Burry would suspect a significant competitive gap or product weakness.
12.10%
3Y revenue/share CAGR under 50% of QCOM's 34.46%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
48.23%
10Y OCF/share CAGR under 50% of QCOM's 310.88%. Michael Burry would worry about a persistent underperformance in cash creation.
24.14%
Below 50% of QCOM's 125.41%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
29.91%
3Y OCF/share CAGR under 50% of QCOM's 144.77%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
101.43%
Net income/share CAGR at 75-90% of QCOM's 114.72%. Bill Ackman would press for strategic moves to boost long-term earnings.
7.87%
Below 50% of QCOM's 56.38%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
12.80%
3Y net income/share CAGR above 1.5x QCOM's 4.62%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
33.75%
Below 50% of QCOM's 222.75%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
16.21%
Below 50% of QCOM's 69.14%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
-3.10%
Negative 3Y equity/share growth while QCOM is at 8.68%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
2216987.49%
10Y dividend/share CAGR above 1.5x QCOM's 422.97%. David Dodd checks if the firm's robust cash flows justify outpacing the competitor's increases.
182.59%
5Y dividend/share CAGR 1.25-1.5x QCOM's 148.18%. Bruce Berkowitz verifies that high dividend hikes remain sustainable, not a sign of over-distribution.
98.80%
3Y dividend/share CAGR 1.25-1.5x QCOM's 88.20%. Bruce Berkowitz checks if the company's short-term profits or payout policy justify these higher hikes.
3.28%
Our AR growth while QCOM is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
-6.05%
Both reduce inventory yoy. Martin Whitman suspects a broader move to lean operations or industry slowdown in demand.
-5.66%
Negative asset growth while QCOM invests at 10.86%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-0.92%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-15.40%
We’re deleveraging while QCOM stands at 895.71%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-1.25%
Our R&D shrinks while QCOM invests at 2.33%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-7.66%
We cut SG&A while QCOM invests at 5.87%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.